Literature DB >> 28556560

Association of MicroRNA-618 Expression With Altered Frequency and Activation of Plasmacytoid Dendritic Cells in Patients With Systemic Sclerosis.

Marzia Rossato1, Alsya J Affandi1, Soley Thordardottir2, Catharina G K Wichers1, Marta Cossu1, Jasper C A Broen1, Frederique M Moret1, Lara Bossini-Castillo3, Eleni Chouri1, Lenny van Bon1, Femke Wolters1, Wioleta Marut1, Maarten van der Kroef1, Sandra Silva-Cardoso1, Cornelis P J Bekker1, Harry Dolstra2, Jacob M van Laar1, Javier Martin4, Joel A G van Roon1, Kris A Reedquist1, Lorenzo Beretta5, Timothy R D J Radstake1.   

Abstract

OBJECTIVE: Plasmacytoid dendritic cells (PDCs) are a critical source of type I interferons (IFNs) that can contribute to the onset and maintenance of autoimmunity. Molecular mechanisms leading to PDC dysregulation and a persistent type I IFN signature are largely unexplored, especially in patients with systemic sclerosis (SSc), a disease in which PDCs infiltrate fibrotic skin lesions and produce higher levels of IFNα than those in healthy controls. This study was undertaken to investigate potential microRNA (miRNA)-mediated epigenetic mechanisms underlying PDC dysregulation and type I IFN production in SSc.
METHODS: We performed miRNA expression profiling and validation in highly purified PDCs obtained from the peripheral blood of 3 independent cohorts of healthy controls and SSc patients. Possible functions of miRNA-618 (miR-618) on PDC biology were identified by overexpression in healthy PDCs.
RESULTS: Expression of miR-618 was up-regulated in PDCs from SSc patients, including those with early disease who did not present with skin fibrosis. IFN regulatory factor 8, a crucial transcription factor for PDC development and activation, was identified as a target of miR-618. Overexpression of miR-618 reduced the development of PDCs from CD34+ cells in vitro and enhanced their ability to secrete IFNα, mimicking the PDC phenotype observed in SSc patients.
CONCLUSION: Up-regulation of miR-618 suppresses the development of PDCs and increases their ability to secrete IFNα, potentially contributing to the type I IFN signature observed in SSc patients. Considering the importance of PDCs in the pathogenesis of SSc and other diseases characterized by a type I IFN signature, miR-618 potentially represents an important epigenetic target to regulate immune system homeostasis in these conditions.
© 2017, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28556560     DOI: 10.1002/art.40163

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  21 in total

Review 1.  Epigenetic Control of Scleroderma: Current Knowledge and Future Perspectives.

Authors:  Pei-Suen Tsou
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

Review 2.  Epigenetics of scleroderma: Integrating genetic, ethnic, age, and environmental effects.

Authors:  Paula S Ramos
Journal:  J Scleroderma Relat Disord       Date:  2019-07-03

Review 3.  Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential.

Authors:  Pei-Suen Tsou; John Varga; Steven O'Reilly
Journal:  Nat Rev Rheumatol       Date:  2021-09-03       Impact factor: 20.543

4.  Dysregulation of Type 1 Interferon Signaling in Systemic Sclerosis: a Promising Therapeutic Target?

Authors:  Minghua Wu; Shervin Assassi
Journal:  Curr Treatm Opt Rheumatol       Date:  2021-10-19

5.  Trimester-specific plasma exosome microRNA expression profiles in preeclampsia.

Authors:  Eric Devor; Donna Santillan; Sabrina Scroggins; Akshaya Warrier; Mark Santillan
Journal:  J Matern Fetal Neonatal Med       Date:  2019-01-30

Review 6.  Pathogenesis and treatment of autoimmune rheumatic diseases.

Authors:  Eric Liu; Andras Perl
Journal:  Curr Opin Rheumatol       Date:  2019-05       Impact factor: 5.006

Review 7.  Involvement of the myeloid cell compartment in fibrogenesis and systemic sclerosis.

Authors:  Gabriela Kania; Michal Rudnik; Oliver Distler
Journal:  Nat Rev Rheumatol       Date:  2019-05       Impact factor: 20.543

Review 8.  The Involvement of MicroRNAs in Modulation of Innate and Adaptive Immunity in Systemic Lupus Erythematosus and Lupus Nephritis.

Authors:  Mohsen Honarpisheh; Paulina Köhler; Ekaterina von Rauchhaupt; Maciej Lech
Journal:  J Immunol Res       Date:  2018-05-08       Impact factor: 4.818

9.  MicroRNA and mRNA profiling in the idiopathic inflammatory myopathies.

Authors:  Joanna E Parkes; Anastasia Thoma; Adam P Lightfoot; Philip J Day; Hector Chinoy; Janine A Lamb
Journal:  BMC Rheumatol       Date:  2020-06-10

Review 10.  MicroRNAs in Autoimmunity and Hematological Malignancies.

Authors:  Mirco Di Marco; Alice Ramassone; Sara Pagotto; Eleni Anastasiadou; Angelo Veronese; Rosa Visone
Journal:  Int J Mol Sci       Date:  2018-10-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.